Human Testing for Inovio’s Hep C Vaccine Planned in 2013
Hepatitis C vaccine by Inovio could be tested in humans by end of year
Jan 9, 2013
John George, Senior Reporter- Philadelphia Business Journal
Inovio Pharmaceuticals Inc. said Wednesday it plans to begin human testing of its hepatitis C DNA vaccine by the end of the year.
Officials at the Blue Bell, Pa., biopharmaceutical company said preclinical studies demonstrated its SynCon HCV vaccine can generate “robust” T-cell responses not only in the blood, but also in the liver — an organ known to suppress T-cell activity.
“The major hurdle to developing therapeutic vaccines for these ailments has been the inability to generate a functional T-cell response in the liver [to combat the hepatitis C virus],” said Dr. J. Joseph Kim, Inovio’s president and CEO.
Continue reading this entire article: